Welcome to our dedicated page for Nocturne Acquisition Corporation news (Ticker: MBTC), a resource for investors and traders seeking the latest updates and insights on Nocturne Acquisition Corporation stock.
Nocturne Acquisition Corporation (NASDAQ: MBTC) is a blank check company incorporated in the Cayman Islands with the core objective of merging, acquiring assets, or reorganizing with one or more businesses. Established on October 28, 2020, and completing its initial public offering on April 5, 2021, Nocturne is guided by experienced technology and crypto operators, aiming to leverage their industry expertise and global network to identify unique, public-ready opportunities.
The company's mission is to partner with innovative crypto or artificial intelligence (AI) technology companies, ushering in the next frontier of technological advancement. Nocturne is currently engaged in significant projects and partnerships, most notably its proposed business combination with Cognos Therapeutics, Inc., a medical technology firm focused on developing advanced devices for treating neurological diseases, including brain and spinal cancers, Alzheimer's, Parkinson's disease, epilepsy, and stroke.
On December 30, 2022, Nocturne and Cognos entered into a Merger Agreement, with the Business Combination expected to close in the fourth quarter of 2023. The combined entity will be renamed Cognos Therapeutics Holdings, Inc., trading on Nasdaq under the symbol 'COGN'. The successful completion of this merger promises to enhance Cognos' capabilities in product development and clinical trials, particularly through their SINNAISTM Implantable Smart Pump, which aims to revolutionize drug delivery for patients suffering from cancer and other neurological conditions.
The transaction is anticipated to provide Cognos with broader access to public capital markets, accelerating research and advancement of their proprietary technologies. The Nocturne team, led by CEO Henry Monzon and CFO Ka Seng (Thomas) Ao, is dedicated to supporting this transformative journey.
In recent developments, Nocturne announced the submission of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (SEC), including a preliminary proxy statement/prospectus related to the proposed Business Combination with Cognos. The filing marks a significant progress towards Cognos becoming a publicly listed company, pending shareholder approval and other customary conditions.
Nocturne's strategic focus on disruptive technologies within the blockchain/crypto and AI sectors, combined with their meticulous approach to acquisitions, positions them as a pivotal player in the evolution of technology-driven markets.
Nocturne Acquisition Corporation (NASDAQ: MBTC, MBTCU, MBTCR) announced a definitive business combination with Cognos Therapeutics, a company focused on innovative medical devices for neurological diseases. The transaction values Cognos at approximately $120 million and involves an all-stock deal where Cognos shareholders will receive Nocturne common stock valued at $10.30 each. The proposed combination, expected to close in the second or third quarter of 2023, aims to enhance Cognos' access to capital for advancing its SINNAIS™ Implantable Smart Pump, designed to improve drug delivery for brain cancer treatment.
FAQ
What is the market cap of Nocturne Acquisition Corporation (MBTC)?
What is Nocturne Acquisition Corporation?
What is the mission of Nocturne Acquisition Corporation?
What are the recent achievements of Nocturne?
What is Cognos Therapeutics?
When is the Business Combination with Cognos expected to close?
What will happen to Nocturne's shares after the merger?
Who are the key executives at Nocturne?
What industries does Nocturne focus on?
How can shareholders participate in the upcoming merger?
Where can I find more information about the Business Combination?
